Cargando…
Third-line therapy for chronic myeloid leukemia: current status and future directions
Chronic myeloid leukemia (CML) is driven by the BCR-ABL1 fusion protein, formed by a translocation between chromosomes 9 and 22 that creates the Philadelphia chromosome. The BCR-ABL1 fusion protein is an optimal target for tyrosine kinase inhibitors (TKIs) that aim for the adenosine triphosphate (AT...
Autores principales: | Cortes, Jorge, Lang, Fabian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7976694/ https://www.ncbi.nlm.nih.gov/pubmed/33736651 http://dx.doi.org/10.1186/s13045-021-01055-9 |
Ejemplares similares
-
Acute myeloid leukemia: current progress and future directions
por: Kantarjian, Hagop, et al.
Publicado: (2021) -
Immune evasion in acute myeloid leukemia: current concepts and future directions
por: Teague, Ryan M, et al.
Publicado: (2013) -
The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions
por: Robak, Tadeusz, et al.
Publicado: (2022) -
TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions
por: Daver, Naval G., et al.
Publicado: (2022) -
Future Approaches for Treating Chronic Myeloid Leukemia: CRISPR Therapy
por: Vuelta, Elena, et al.
Publicado: (2021)